Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 361

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 361
---
177 the public. Advances in sequencing technology and rising awareness and demand for genetic testing support this growth. Further, according to a public report titled “The Cost of Sequencing a Human Genome”, published by the National Human Genome Research Institute, dated November1, 2021, technological advances have reduced the costs of genetic sequencing, increasing their accessibility. To boost market adoption, we expect to launch the consortium to offer our partners exclusive genomic services with competitive pricing, quick result turnaround times, pre- and post -testsupport, and market development initiatives. This consortium will be launched in a phased approach, as we build relationships, assess local market needs, and locate the results from our offerings to ensure a strong market fit. Our expertise in delivering precise, personalized results and developing innovative products, some of which are suitable for in -homeuse, is fundamental to our operations. We utilize both dry and wet labs, including laboratories from strategic partners as part of a hybrid operational model, and integrate multi -modaldata, allowing us to cater to the needs of patients, users, insurance companies, pharma, and other health stakeholders within the specific markets where we offer our services. Currently, our products are available, particularly targeting underserved markets in Latin America. By launching a suite of services and supporting our partners in these regions, we aim to reshape the relationship between consumers, patients, healthcare professionals and providers, and transform healthcare. Our competitive advantage is to include developing market specific end -to -endservices, leveraging both our own and our strategic partners’ laboratories, including local market product adaptation, providing pre- and post -testassessments (technical and commercial onboarding and training) for market co -developmentassistance, and, in certain circumstances, will plan to offer teleconsultations with AI Agents, in addition to consultations with medical geneticists and/or epigenetic specialists to interpret results and accompany in the decision making. We deliver personalized reports and have the necessary operational experience for import and export logistics, as well as the know -howto process and sequence samples effectively. We are also accumulating biological, clinical and lifestyle data across various health fields, enabling us to develop additional innovations. Mission and Strategy We aim to keep people healthy by revolutionizing personal health management, by delivering a comprehensive suite of services spanning prevention, diagnosis and prognosis, integrating a wide range of clinical, biological, and lifestyle data with advanced artificial intelligence, empowering people to make informed health choices and live healthier lives. Our strategy for long -termsustainable expansion is grounded in fundamental drivers that form the core